Skip to main content

Breast Cancer Clinical Trials

Review the breast cancer clinical trials on this list and use the filters to refine the results by age and location. Some clinical trials are held at NCI-Designated Cancer Centers and may be supported by other organizations.

You can find more information about the types and phases of clinical trials and what to expect or use our Steps to Find a Clinical Trial.

Trials 276-300 of 909

Magseed Enabled Long-Term Localization of Axillary Lymph Nodes
Status: Active
Location: 2 locations
Radiofrequency Electromagnetic Fields Therapy using the TheraBionic P1 Device prior to Surgery for the Treatment of Stage I-III Resectable Breast Cancer
Status: Active
Location: 2 locations
Image Guided Radiation Therapy with MRI for the Treatment of Cancer, CONFIRM Study
Status: Active
Location: 2 locations
Delayed Sentinel Lymph Node Biopsy in Ductal Cancer in Situ
Status: Active
Location: Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center, Houston, Texas
Comparing Length of Treatment with Immunotherapy in Patients with Advanced Solid Tumors
Status: Active
Location: University of Pittsburgh Cancer Institute (UPCI), Pittsburgh, Pennsylvania
Local Consolidative Therapy to Extend the Efficacy of Systemic Therapy in Oligoprogressive Metastatic Cancer, EXTEND-OP Trial
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Neurotization of the Nipple Areolar Complex to Restore Sensation for Patients with Breast Cancer Undergoing Nipple Sparing Mastectomy and Reconstruction
Status: Active
Location: Mayo Clinic in Florida, Jacksonville, Florida
Abemaciclib Alone or in Combination with Hydroxychloroquine for the Treatment of Patients with Breast Cancer, ABBY Trial
Status: Active
Location: University of Pennsylvania/Abramson Cancer Center, Philadelphia, Pennsylvania
Vitamin D Supplementation for the Improvement of Pathologic Complete Response in Vitamin D Deficient Patients Receiving Neoadjuvant Chemotherapy for Operable Triple Negative Breast Cancer
Status: Active
Location: Wake Forest University Health Sciences, Winston-Salem, North Carolina
Concurrent WOKVAC Vaccination, Chemotherapy, and HER2-Targeted Monoclonal Antibody Therapy before Surgery for the Treatment of Patients with Breast Cancer
Status: Active
Location: Fred Hutch/University of Washington/Seattle Children's Cancer Consortium, Seattle, Washington
Pembrolizumab Plus Combination Chemotherapy before Surgery for the Treatment of Stage I Triple Negative Breast Cancer
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Safety of Continuing HER-2 Directed Therapy in Overt Left Ventricular Dysfunction
Status: Active
Location: UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California
Trastuzumab, Pertuzumab and Docetaxel With or Without Carboplatin for the Treatment of Stage II-III HER2 Positive Breast Cancer, NeoTHERa Trial
Status: Active
Location: University of Kansas Cancer Center, Kansas City, Kansas
Hypofractionated Radiotherapy Before or After Breast Surgery for the Treatment of Patients with Non-Metastatic Breast Cancer
Status: Active
Location: 2 locations
Riluzole for the Improvement of Brain-Derived Neuropathic Factor Levels in Cancer Survivors Experiencing Cancer-Related Cognitive Impairment
Status: Active
Location: UC Irvine Health/Chao Family Comprehensive Cancer Center, Orange, California
Turkey Tail Mushroom for Treating Post-Menopausal Women with HER2-Negative ER-Positive Breast Cancer Undergoing Surgery
Status: Active
Location: Mayo Clinic in Arizona, Scottsdale, Arizona
Anthracycline-Free Chemotherapy and Immunotherapy Regimen for the Treatment of Triple-Negative Breast Cancer Patients at Risk for Cardiotoxicity, NeoCARD Trial
Status: Active
Location: Medical University of South Carolina, Charleston, South Carolina
Study of Patritumab Deruxtecan Plus Pembrolizumab With Other Anticancer Agents in Participants With High-Risk Early-Stage Triple-Negative or Hormone Receptor-Low Positive/HER-2 Negative Breast Cancer (MK-1022-010, HERTHENA-Breast-03)
Status: Active
Location: UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California
Evaluation of Immune Cells and Response-Adapted Chemoimmunotherapy before Surgery for the Treatment of Triple-Negative Breast Cancer, The NeoTRACT Trial
Status: Active
Location: University of Kansas Hospital-Westwood Cancer Center, Westwood, Kansas
Capecitabine or Trastuzumab Emtansine with Radiation Therapy for the Treatment of High-Risk Stage I-IIIB Breast Cancer
Status: Active
Location: University of Virginia Cancer Center, Charlottesville, Virginia
Shorted Adjuvant Regional Nodal Irradiation for the Treatment of Patients with Lymph Node-Positive and High-Risk Lymph Node Negative Invasive Breast Cancer
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
A Vaccine (Dendritic Cell 1) for the Treatment of Patients with HER-2 Positive Breast Cancer, NATASHA Study
Status: Active
Location: Moffitt Cancer Center, Tampa, Florida
Tamoxifen Citrate or Aromatase Inhibitor in Treating Elderly Patients with Estrogen Receptor Positive Breast Cancer That Can Be Removed by Surgery
Status: Active
Location: Siteman Cancer Center at Washington University, Saint Louis, Missouri
Reduced Adjuvant Systemic Therapy for the Treatment of Patients with Early Breast Cancer Who Experienced a Pathological Complete Response After Neoadjuvant Systemic Therapy and Do Not Have Molecular Residual Disease, MolecularPCR Trial
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Darolutamide Alone or in Combination with Standard Therapy before Surgery for the Treatment of Stage II-IIIA, Androgen Receptor Positive, Triple-Negative Breast Carcinoma
Status: Active
Location: Vanderbilt University/Ingram Cancer Center, Nashville, Tennessee